Press Releases

November 12, 2024
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass. , Nov. 12, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc.  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in the
November 7, 2024
Collegium Reports Record Third Quarter 2024 Financial Results

– Generated Record Q3’24 Net Revenue of $159.3 Million , Up 17% Year-over-Year, Driven by Record Belbuca ® Revenue of $53.2 Million and Record Xtampza ® ER Revenue of $49.5 Million – – Achieved Q3’24 GAAP Net Income of $9.3 Million – – Delivered Record Q3’24 Adjusted EBITDA of $105.1 Million , Up

November 7, 2024
Collegium Appoints Vikram Karnani as Chief Executive Officer
Vikram Karnani is a Proven Industry Leader with Extensive Experience Growing Commercial Biopharmaceutical Businesses STOUGHTON, Mass. , Nov. 07, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the
October 24, 2024
Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024
STOUGHTON, Mass. , Oct. 24, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc.  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report third quarter 2024
September 4, 2024
Collegium Completes Acquisition of Ironshore Therapeutics
–   Adds Commercial Product Jornay PM ® , Establishing Collegium’s Presence in Neurology (ADHD) – – Collegium Updates 2024 Financial Guidance to Reflect Expected Immediate Accretion from the Ironshore Acquisition – – 2024 Product Revenues, Net Expected in the Range of $620.0 Million to $635.0
August 28, 2024
Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024
STOUGHTON, Mass. , Aug. 28, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that eight poster presentations highlighting
August 8, 2024
Collegium Reports Second Quarter 2024 Financial Results
– Generated Q2’24 Net Revenue of $145.3 Million and Record Belbuca ® Revenue of $52.2 Million , Up 7% and 21% Year-over-Year, Respectively –         – Achieved Q2’24 GAAP Net Income of $19.6 Million , Up 51% Year-over-Year – – Delivered Q2’24 Adjusted EBITDA of $96.0 Million , Up 12% Year-over-Year
July 29, 2024
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
–   Adds Commercial Product Jornay PM ® , Establishing Collegium’s Presence in Neurology (ADHD) – – H1’24 Jornay PM Prescriptions Grew 32% Year-over-Year – –   Transaction Expected to be Immediately Accretive to Adjusted EBITDA – – Acquisition Funded by Collegium’s Cash on Hand and New Five-Year
July 25, 2024
Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024
STOUGHTON, Mass. , July 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc.  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report second quarter 2024
May 29, 2024
Collegium to Participate in Jefferies Global Healthcare Conference
STOUGHTON, Mass. , May 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc.  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a
May 13, 2024
Collegium Announces $35 Million Accelerated Share Repurchase Program
STOUGHTON, Mass. , May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share
May 9, 2024
Collegium Reports First Quarter 2024 Financial Results
– Generated Q1’24 Net Revenue of $144.9 Million – – Delivered Q1’24 Record Belbuca ® Revenue of $50.7 Million ; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1’24 GAAP Net Income of $27.7 Million vs. Q1’23 GAAP Net Loss of $(17.4) Million – – Delivered Q1’24 Adjusted EBITDA of $92.4
May 9, 2024
Collegium Announces CEO Transition
– Joe Ciaffoni to Step Down as President and Chief Executive Officer – – Board Chairman Michael Heffernan to Serve as Interim President and Chief Executive Officer – – Board of Directors has Initiated the Search for a Successor – STOUGHTON, Mass. , May 09, 2024 (GLOBE NEWSWIRE) -- Collegium
April 25, 2024
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
STOUGHTON, Mass. , April 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc.  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report first quarter 2024
April 3, 2024
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
STOUGHTON, Mass. , April 03, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc.  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a
February 22, 2024
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
– Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $104.2 Million and $367.0 Million – – Ended 2023 with
January 3, 2024
Collegium Provides 2024 Financial Guidance
– Product Revenues, Net Expected in the Range of $580.0 Million to $595.0 Million – – Adjusted Operating Expenses* Expected in the Range of $120.0 Million to $125.0 Million – – Adjusted EBITDA* Expected in the Range of $380.0 Million to $395.0 Million – – $150.0 Million Share Repurchase Program